Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32240071.
- Also identified by DOI 10.1200/JOP.19.00517 and PMC identifier 7427420.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG). We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM. GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw. Our study has important implications in the care of MM, particularly in countries/areas with limited resources.
Medical subject headings
- Multiple Myeloma